PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an ...